JP2025504768A5 - - Google Patents

Info

Publication number
JP2025504768A5
JP2025504768A5 JP2024539747A JP2024539747A JP2025504768A5 JP 2025504768 A5 JP2025504768 A5 JP 2025504768A5 JP 2024539747 A JP2024539747 A JP 2024539747A JP 2024539747 A JP2024539747 A JP 2024539747A JP 2025504768 A5 JP2025504768 A5 JP 2025504768A5
Authority
JP
Japan
Prior art keywords
ionic liquid
liquid according
pharmaceutical composition
mol
cation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050671 external-priority patent/WO2023144742A1/en
Publication of JP2025504768A publication Critical patent/JP2025504768A/ja
Publication of JP2025504768A5 publication Critical patent/JP2025504768A5/ja
Pending legal-status Critical Current

Links

JP2024539747A 2022-01-26 2023-01-26 神経疾患の予防または治療のためのイオン液体ベースの製剤 Pending JP2025504768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT117761 2022-01-26
PT11776122 2022-01-26
PCT/IB2023/050671 WO2023144742A1 (en) 2022-01-26 2023-01-26 Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Publications (2)

Publication Number Publication Date
JP2025504768A JP2025504768A (ja) 2025-02-19
JP2025504768A5 true JP2025504768A5 (https=) 2025-12-03

Family

ID=85936842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539747A Pending JP2025504768A (ja) 2022-01-26 2023-01-26 神経疾患の予防または治療のためのイオン液体ベースの製剤

Country Status (6)

Country Link
US (1) US12514845B2 (https=)
EP (1) EP4469044B1 (https=)
JP (1) JP2025504768A (https=)
CN (1) CN118524836B (https=)
CA (1) CA3242202A1 (https=)
WO (1) WO2023144742A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012201058A1 (en) 2003-08-29 2012-03-15 President And Fellows Of Harvard College Inhibitors of cellular necrosis
KR20080051246A (ko) 2006-12-05 2008-06-11 (주)에스에이치제약 뇌신경계 질환의 예방 또는 치료용 및 ｎａｄｐｈ 산화효소활성억제용 약학적 조성물
WO2010078258A1 (en) 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Compounds comprising two or more biologically functional ions and method of treating parkinson's disease
EP2554163A4 (en) 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
US8673956B2 (en) 2011-12-02 2014-03-18 Board Of Trustees Of The University Of Alabama Imido-acid salts and methods of use
CN103330708B (zh) 2013-07-23 2014-11-26 苏州大学 5-(3’，5’-二甲氧基苯甲撑基)-2-硫代-咪唑-4-酮在制备治疗脑血管疾病的药物中的应用
WO2015129527A1 (ja) 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
EP3129102B1 (en) 2014-04-07 2025-06-18 The United States of America, as represented by The Secretary, Department of Health and Human Services Iodonium analogs as inhibitors of nadph oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
JP2015227329A (ja) 2014-05-09 2015-12-17 サントリーホールディングス株式会社 メトキシフラボンを含むＮＯＸ阻害剤及びＮＦκＢ阻害剤
WO2018129421A1 (en) 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR20200022193A (ko) 2018-08-22 2020-03-03 한림대학교 산학협력단 결핵성 흉막 섬유증 예방 또는 치료용 약학 조성물
WO2020205937A1 (en) 2019-04-01 2020-10-08 Emory University Hyaluronic acid nanoparticles comprising nadph oxidases inhibitors and uses in treating cancer
CN111138376A (zh) 2019-12-24 2020-05-12 中山大学 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用
US12552779B2 (en) * 2020-07-10 2026-02-17 Duksung Women's University Industry-Academic Cooperation Foundation 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-on and derivative thereof, preparation method therefor, and composition comprising same for preventing, alleviating or treating neurodegenerative diseases

Similar Documents

Publication Publication Date Title
US11813256B2 (en) High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
CN103550195A (zh) 用于治疗多发硬化症的s1p受体调节剂
CA2294589A1 (en) Composition for controlling mood disorders in healthy individuals
JP2026035701A5 (https=)
RS64481B1 (sr) Lečenje alchajmerove bolesti kod posebne populacije pacijenata
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023548429A5 (https=)
WO2023155837A1 (zh) 具有镇痛和/或止痒功能的药物组合物及其用途
JP2019531286A5 (https=)
MXPA97002732A (en) Use of indol derivatives for the treatment of different enfermeda
JP2020533402A5 (https=)
JP2000080036A (ja) 新規な治療方法
JP2025504768A5 (https=)
US11622954B2 (en) Estrogen receptor ligands, compositions and methods related thereto
JP2023518640A5 (https=)
JP2022505184A5 (https=)
ES2254140T3 (es) Uso de antidepresivos triciclicos para el tratamiento de cefalea.
JPS5955829A (ja) 脳内の器質性障害に起因する精神機能症状の改善・治療剤
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
JP2024541770A5 (https=)
JP2013018729A (ja) アルツハイマー病治療剤の作用増強経口用剤
JP2005507884A5 (https=)